688197.SHG Shouyao Holdings (Beijing) Co. Ltd. A
- Market cap
- CNY 5.19B
- P/E
- -
- P/B
- 7.55x
- ROE
- -9.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688197.SHG undervalued?
Graham numberThe Graham number of Shouyao Holdings (Beijing) Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shouyao Holdings (Beijing) Co. Ltd. A fundamental analysis
No fundamental analysis for Shouyao Holdings (Beijing) Co. Ltd. A yet.
Shouyao Holdings (Beijing) Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shouyao Holdings (Beijing) Co. Ltd. A
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.
Full company profileShouyao Holdings (Beijing) Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shouyao Holdings (Beijing) Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 11.5M | 7.02M | 13.0M | 1.83M | 5.23M | 3.94M | 8.67M | 124M |
| Gross Profit | 10.1M | 7.01M | 13.0M | 1.82M | 5.12M | 3.90M | 8.40M | 121M |
| Operating Income | -38.4M | -336M | -147M | -195M | -212M | -226M | -146M | -66.8M |
| EBITDA | -34.7M | -329M | -139M | -167M | -178M | -205M | -122M | -59.1M |
| Net Income | -39.6M | -330M | -145M | -174M | -186M | -212M | -129M | -59.4M |
| EPS | -0.36 | -2.96 | -1.30 | -1.17 | -1.25 | -1.43 | -0.87 | -0.40 |
| Balance Sheet | ||||||||
| Total Assets | 219M | 182M | 58.2M | 1.30B | 1.11B | 922M | 791M | 745M |
| Total Liabilities | 44.3M | 35.7M | 56.7M | 92.7M | 91.2M | 113M | 111M | 110M |
| Shareholders' Equity | 174M | 146M | 1.50M | 1.21B | 1.02B | 809M | 680M | 636M |
| Cash & Short-term Investments | 142M | 142M | 24.5M | 1.19B | 530M | 22.7M | 17.6M | 17.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | -84.7M | -93.2M | -104M | -129M | -180M | -197M | -158M | - |
| Capital Expenditure | 1.14M | 3.36M | 7.35M | 20.7M | 3.83M | 8.57M | 3.20M | 50.3M |
| Free Cash Flow | -85.8M | -96.5M | -111M | -150M | -183M | -205M | -161M | -199M |
| Ratios | ||||||||
| ROE | -22.8% | -225.5% | -9,650.4% | -14.4% | -18.2% | -26.2% | -18.9% | -9.3% |
| ROA | -18.1% | -181.3% | -249.1% | -13.4% | -16.7% | -23.0% | -16.3% | -8.0% |
| Net Profit Margin | -343.0% | -4,703.2% | -1,112.0% | -9,512.7% | -3,548.8% | -5,376.4% | -1,486.4% | -47.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shouyao Holdings (Beijing) Co. Ltd. A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CNY 128K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shouyao Holdings (Beijing) Co. Ltd. A
- Insiders 72.32%
- Institutions 7.01%
- Public & others 20.67%
- Shares outstanding 149M
- Free float 55.5M
Shouyao Holdings (Beijing) Co. Ltd. A company profile
- Company name
- Shouyao Holdings (Beijing) Co. Ltd. A
- Ticker
- 688197.SHG
- ISIN
- CNE1000062V6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 184
- Fiscal year end
- December
- Address
- Building 20, Beijing, China, 100195
- Phone
- 86 10 8885 7906
- Website
- shouyaoholding.com
About Shouyao Holdings (Beijing) Co. Ltd. A
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.
Shouyao Holdings (Beijing) Co. Ltd. A management
10- Mr. Wenjun LiChairman of the Board & GM · born 1967
- Ms. Yajie WangAccounting Supervisor & Chief Financial Officer · born 1970
- Mr. Xin He XuSenior Manager of Pharmacy Department & Director · born 1974
- Ms. Ying Li ZhangBoard Secretary · born 1984
- Mr. Yan ZhuDeputy General Manager · born 1981
- Mr. Xi Jie LiuDeputy General Manager · born 1976
- Mr. Li Min YangDeputy General Manager · born 1976
- Ms. Ying Hui SunDeputy General Manager · born 1980
- Ms. An Na WangDirector of Clinical Medicine · born 1981
- Ms. Jing Can WangDirector of Registration · born 1983